1. Home
  2. PLSE vs PHVS Comparison

PLSE vs PHVS Comparison

Compare PLSE & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PLSE
  • PHVS
  • Stock Information
  • Founded
  • PLSE 2014
  • PHVS 2015
  • Country
  • PLSE United States
  • PHVS Switzerland
  • Employees
  • PLSE N/A
  • PHVS N/A
  • Industry
  • PLSE Medical/Dental Instruments
  • PHVS Biotechnology: Pharmaceutical Preparations
  • Sector
  • PLSE Health Care
  • PHVS Health Care
  • Exchange
  • PLSE Nasdaq
  • PHVS Nasdaq
  • Market Cap
  • PLSE 1.1B
  • PHVS 980.9M
  • IPO Year
  • PLSE 2016
  • PHVS 2021
  • Fundamental
  • Price
  • PLSE $16.07
  • PHVS $23.80
  • Analyst Decision
  • PLSE Buy
  • PHVS Buy
  • Analyst Count
  • PLSE 1
  • PHVS 6
  • Target Price
  • PLSE $22.00
  • PHVS $37.17
  • AVG Volume (30 Days)
  • PLSE 202.2K
  • PHVS 33.8K
  • Earning Date
  • PLSE 08-11-2025
  • PHVS 08-13-2025
  • Dividend Yield
  • PLSE N/A
  • PHVS N/A
  • EPS Growth
  • PLSE N/A
  • PHVS N/A
  • EPS
  • PLSE N/A
  • PHVS N/A
  • Revenue
  • PLSE N/A
  • PHVS N/A
  • Revenue This Year
  • PLSE N/A
  • PHVS N/A
  • Revenue Next Year
  • PLSE $700.00
  • PHVS N/A
  • P/E Ratio
  • PLSE N/A
  • PHVS N/A
  • Revenue Growth
  • PLSE N/A
  • PHVS N/A
  • 52 Week Low
  • PLSE $13.50
  • PHVS $11.51
  • 52 Week High
  • PLSE $25.00
  • PHVS $25.76
  • Technical
  • Relative Strength Index (RSI)
  • PLSE 50.73
  • PHVS 73.80
  • Support Level
  • PLSE $15.19
  • PHVS $17.63
  • Resistance Level
  • PLSE $17.27
  • PHVS $25.76
  • Average True Range (ATR)
  • PLSE 0.78
  • PHVS 1.51
  • MACD
  • PLSE 0.20
  • PHVS 0.69
  • Stochastic Oscillator
  • PLSE 52.76
  • PHVS 82.19

About PLSE Pulse Biosciences Inc (DE)

Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Share on Social Networks: